Medtronic Limited Completes Enrollment in Global Head-to-Head Stent-Safety Study

Published: Feb 02, 2009

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT), today announced the completion of enrollment in PROTECT,1 the company’s global study comparing its Endeavor drug-eluting stent (DES) to Johnson & Johnson’s Cypher® DES. A landmark study of groundbreaking devices used to treat coronary artery disease, PROTECT is the first and largest randomized controlled trial (RCT) of its kind.

Back to news